Click here to view the course video.
Click here to download a PDF of the webcast transcript
Click the below links for additional resources.
- Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
- Overcoming barriers to the initiation of insulin therapy
- Biosimilar insulins
- Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
- Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)